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Aims Traditional prognostic risk assessment in patients undergoing non-invasive imaging is based upon a limited selection of
clinical and imaging findings. Machine learning (ML) can consider a greater number and complexity of variables. There-
fore, we investigated the feasibility and accuracy of ML to predict 5-year all-cause mortality (ACM) in patients under-




The analysis included 10 030 patients with suspected coronary artery disease and 5-year follow-up from the COronary
CT Angiography EvaluatioN For Clinical Outcomes: An InteRnational Multicenter registry. All patients underwent
CCTA as their standard of care. Twenty-five clinical and 44 CCTA parameters were evaluated, including segment sten-
osis score (SSS), segment involvement score (SIS), modified Duke index (DI), number of segments with non-calcified,
mixed or calcified plaques, age, sex, gender, standard cardiovascular risk factors, and Framingham risk score (FRS). Ma-
chine learning involved automated feature selection by information gain ranking, model building with a boosted ensem-
ble algorithm, and 10-fold stratified cross-validation. Seven hundred and forty-five patients died during 5-year follow-up.
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Machine learning exhibited a higher area-under-curve compared with the FRS or CCTA severity scores alone (SSS, SIS,
DI) for predicting all-cause mortality (ML: 0.79 vs. FRS: 0.61, SSS: 0.64, SIS: 0.64, DI: 0.62; P, 0.001).
Conclusions Machine learning combining clinical and CCTA data was found to predict 5-year ACM significantly better than existing
clinical or CCTA metrics alone.
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Introduction
Coronary computed tomography angiography (CCTA) is an accur-
ate non-invasive technique for the diagnosis and exclusion of ob-
structive coronary artery disease (CAD).1 In addition to coronary
stenosis, CCTA also allows for evaluation of coronary atheroscler-
osis extent, severity, distribution, and composition. Beyond clinical
variables, these imaging findings add incremental utility for predic-
tion of future adverse events.2 –4
Machine learning (ML) is a field of computer science that uses
computer algorithms to identify patterns in large datasets with a
multitude of variables, and can be used to predict various outcomes
based on the data. Machine learning algorithms typically build a
model from test inputs in order to make data-driven predictions
or decisions. In recent years, ML techniques have emerged as highly
effective methods for prediction and decision-making in a multitude
of disciplines, including internet search engines, customized adver-
tising, natural language processing, finance trending, and robotics.5,6
There is consensus in the ML community on the superior perform-
ance of aggregation approaches, known as ensemble methods such
as ‘boosting’, and therefore we have chosen a boosting approach for
this study.7 To date, the benefit of utilizing ML with data from CCTA
to predict hard-prognostic endpoints has not been evaluated on a
large scale. Therefore, the aim of this study was to utilize a large,
prospective multinational registry of patients undergoing CCTA to
assess the feasibility and accuracy of ML to predict 5-year all-cause
mortality (ACM), and then compare the performance to existing
clinical or CCTA metrics.
Methods
Study population
Ten thousand and thirty stable patients with suspected CAD and with
5-year follow-up from the COronary CT Angiography EvaluatioN For
Clinical Outcomes: An InteRnational Multicenter (CONFIRM) registry
were studied.2,8 COronary CT Angiography EvaluatioN For Clinical
Outcomes: An InteRnational Multicenter is an international, multicen-
tre, observational registry collecting clinical, procedural, and follow-up
data of patients undergoing clinically indicated CCTA (enrolled 2004–
10).2 The study complies with the Declaration of Helsinki, all patients
provided informed consent for inclusion in the registry, and institutional
review board approval was obtained at each centre. Individuals with
known CAD (defined as prior myocardial infarction (MI) or revascular-
ization) or those with early revascularization after the index CCTA
(defined as within 90 days) were excluded from the present study.
Clinical data
A structured interview was conducted before CCTA to collect informa-
tion on symptoms and the presence of cardiovascular risk factors
(Figure 1). Hypertension was defined as a history of blood pressure
.140 mmHg or treatment with antihypertensive medications. Diabetes
mellitus was defined by a diagnosis made previously by a physician and/
or use of insulin or oral hypoglycaemic agents. Smoking history was de-
fined as current smoking, or cessation of smoking within the last 3
months. Family history of premature CAD was defined as MI in a first-
degree relative ,55 years (male) or ,65 years (female). Dyslipidaemia
was defined as known but untreated dyslipidaemia, or current treatment
with lipid-lowering medications. In addition, blood cholesterol levels of
the lipid test nearest to the index examination were recorded. The pri-
mary outcome of the study was ACM recorded as a binary variable, and
the study end-point was time to ACM. In U.S. sites, death status was as-
certained by querying the Social Security Death Index. In non-U.S. sites,
follow-up data were collected by mail or telephone contact with the
patients or their families; events were verified by hospital records or




Coronary computed tomographic angiography investigations were per-
formed on ≥64-detector row scanners from a variety of vendors (Light-
speed VCT, GE Healthcare, Milwaukee, WI, USA; Somatom Definition
CT, Siemens, Erlangen, Germany). The imaging protocol adhered to
Society of Cardiovascular Computed Tomography guidelines.9 Detailed
methodology has been previously published.2
Image analysis
All scans were analysed by level III-equivalent cardiologists or radiolo-
gists. Images were evaluated by an array of post-processing techniques,
including axial, multi-planar reformat, maximum intensity projection,
and short-axis cross-sectional views.
Coronary segments were scored visually for the presence and com-
position of coronary plaque, and degree of luminal stenosis using a
16-segment coronary artery model.9 In each segment, plaques were
classified as non-calcified, mixed, or calcified. The presence of coronary
calcification was determined visually in contrast-enhanced datasets.
Non-calcified plaque was defined as a tissue structure .1 mm2
that could be clearly discriminated from the vessel lumen and surround-
ing tissue, with a density below the blood-pool. Plaques meeting this
definition and in addition showing any calcified areas were classified
as mixed. Severity of luminal stenosis in each segment was scored
visually: 0 (none, 0%), 1 (mild, 1–49%), 2 (moderate, 50–69%), or
3 (severe, ≥70%).
For purposes of classification for per-vessel analyses, we considered
four arterial territories: left main (LM), left anterior descending (LAD)
and its diagonal branches, left circumflex (LCx) and its obtuse marginal
branches, and the right coronary artery (RCA). The posterior descend-
ing artery and posterolateral branch were considered as part of the RCA
or LCx system, depending on recorded dominance.
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Figure 1 Feature selection. Forty-four coronary computed tomographic angiography variables (blue) and 25 clinical variables (green) were
available. Information gain ranking was used to evaluate the worth of each variable by measuring the entropy gain with respect to the outcome,
and then rank the attributes by their individual evaluations (top to bottom). Only attributes resulting in information gain .0 (above red line) were
subsequently used in boosting. This figure shows the results from one representative fold of the cross-validation procedure. Variables are followed
by units, or categorical range in parentheses—full details in Supplementary material online, Appendix. ACM, all-cause mortality; BMI, body mass
index; CAD, coronary artery disease; CCS, coronary calcium score; CVA, cerebrovascular accident; D, diagonal; DM, diabetes mellitus; EF, ejection
fraction; F, female; FRS, Framingham risk score; HDL, high-density lipoprotein; HTN, hypertension; LM, left main; LAD, left anterior descending
artery; LCX, left circumflex; LDL, low-density lipoprotein M, male; NoV, number of vessels; Nr., number of; OM, obtuse marginal; PAD, peripheral
arterial disease; PL, posterolateral branch; RCA, right coronary artery; sev, severe; SSS, segment stenosis score; SIS, segment involvement score.
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Comparative metrics
Clinical and CCTA parameters were summarized with a number of
existing metrics to allow direct comparison with the ML method.
Clinical data
Framingham risk score (FRS) was used as a comparative summary metric
for clinical parameters. Framingham risk score was calculated with the
established categorical model using low-density lipoprotein cholesterol
according to Wilson et al.10 Although, FRS was originally validated for
the 10-year risk of coronary heart disease in asymptomatic patients,
this is a commonly adopted strategy given the absence of any more suit-
able clinical risk score for symptomatic patients or shorter follow-up
periods. Moreover, it frames the accuracy of the ML-model in the con-
text of a widely used and understood clinical score.2–4
Coronary computed tomographic angiography data
Three composite CCTA-based scores assessing overall plaque burden
and severity of CAD were derived. First, the segment stenosis score
(SSS) was employed as an overall measure of coronary plaque extent.2
For each patient, individual coronary segments were scored 0–3 based
on luminal diameter stenosis, and then summed to yield a total SSS (0–
48). Second, the segment involvement score (SIS) was calculated as a
measure of overall coronary plaque distribution, by summation of the
absolute number of coronary segments with plaque (0–16).2 Third,
the modified Duke prognostic CAD index (DI) was used, which cate-
gorizes patients into the following subsets, each with an increasing
risk of 5-year death: (1) ,50% stenosis, (2) ≥2 stenoses 30–49% (in-
cluding 1 artery with proximal disease) or 1 vessel with 50–69% sten-
osis, (3) 2 stenoses 50–69% or 1 vessel with ≥70% stenosis, (4)
3 stenoses 50–69% or 2 vessels with ≥70% stenosis or proximal left
anterior descending stenosis ≥70%, (5) 3 vessels ≥70% stenoses or 2
vessels ≥70% stenosis with proximal LAD, and (6) LM stenosis ≥50%.2
Machine learning
Forty-four CCTA parameters and 25 clinical parameters were available
(Figure 1). Machine learning involved automated feature selection by in-
formation gain ranking, model building with a boosted ensemble algo-
rithm, and 10-fold stratified cross-validation for the entire process
(Figure 2).11 – 14 Machine learning techniques were implemented in the
open-source Waikato Environment for Knowledge Analysis platform
(3.7.12).14,15
Feature selection
Feature selection was performed using a technique known as ‘informa-
tion gain attribute ranking’.11 Information gain is defined as a measure of
the effectiveness of an attribute in classifying the training data. It is mea-
sured as the amount by which the entropy of the class decreases, which
reflects the additional information about the class provided by the attri-
bute. Only attributes resulting in information gain.0 were subsequent-
ly used in model building (Figure 1).
Model building
Predictive classifiers for ACM prediction were developed by an ensem-
ble classification approach (‘boosting’), employing an iterative Logit-
Boost algorithm using decision stumps (single-node decision trees) for
each feature-selected variable as base classifiers.12,16 The principle be-
hind ML ensemble boosting is that a set of weak base classifiers can
be combined to create a single strong classifier by iteratively adjusting
their appropriate weighting according to misclassifications. A series of
base classifier predictions and an updated weighting distribution are
produced with each iteration. These predictions are then combined
by weighted majority voting to derive an overall classifier–the ‘Logit-
Boost score’ or risk probability estimate (%).
Cross-validation
The performance and general error estimation of the entire ML process
(feature selection and LogitBoost) was assessed using stratified 10-fold
cross-validation which is currently the preferred technique in data min-
ing.13,17 The main advantages of this validation technique compared with
the conventional split-sample (test and validation) approach are: (i) it re-
duces the variance in prediction error leading to a more accurate esti-
mate of model prediction performance; (ii) it maximizes the use of data
for both training and validation, without overfitting or overlap between
test and validation data; and (iii) guards against testing hypotheses sug-
gested by arbitrarily split data (Type III errors).13
Briefly, the dataset is randomly divided into 10 equal folds, each with
approximately the same number of events; 10 validation experiments
are then performed, with each fold used in turn as the validation set,
and the remaining 9 folds as the training set. Therefore, each data point
is used once for testing and 9 times for training, and the result is 10 ex-
perimental LogitBoost models trained on 90% fractions. The validation
results from 10 experimental models are then combined to provide a
measure of the overall performance (Figure 2).13
Statistical analysis
Continuous variables are presented as mean+ SD. The performance of
ML to predict ACM was compared with CCTA severity scores (SSS, SIS,
and DI) and FRS, using receiver-operating characteristic (ROC) analysis
and pairwise comparisons according to Delong et al.18 For ML scores,
the optimal thresholds for three risk categories (low, intermediate,
and high) were defined using the two-graph-ROC (TG-ROC) technique
at the 90% accuracy level.19 Calibration of the LogitBoost model was as-
sessed using the Brier score method (range: 0–1)—lower scores being
consistent with better model calibration.20 Calibration was also as-
sessed graphically with plots showing the observed and predicted pro-
portion of events, grouped by decile of risk.21 For all analyses, surviving
Figure 2 Computational methods. Machine learning involved
automated feature selection by information gain ranking, model
building with a boosted ensemble algorithm (LogitBoost), and
10-fold stratified cross-validation.
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patients were right censored to their follow-up date. All statistical tests
were two tailed and P, 0.05 was considered significant.
Results
Study population
Table 1 describes the baseline characteristics of the study popula-
tion. There was no drop-out in this analysis and primary outcome
data were determined for all patients. Seven hundred and forty-five
patients died during the mean follow-up time of 5.4+1.4 years.
Feature selection
Figure 1 shows the results from one representative fold of the
10-fold cross-validation procedure. In this representative fold, using
the information gain ranking criteria, 54 of the available 69 variables
were selected for the LogitBoost model (19 clinical and 35 from
CCTA). As expected, age was the highest ranked feature for ACM
prediction, but 8 of the top 10 ranked features were CCTA-derived
factors rather than clinical.
Prediction all-cause mortality
Machine learning exhibited a higher area-under-the-curve (AUC)
compared with FRS or CCTA data alone for prediction of 5-year
ACM (ML: 0.79 vs. FRS: 0.61, SSS: 0.64, SIS: 0.64, DI: 0.62; P,
0.001 for all) (Figure 3). Segment stenosis score and SIS were super-
ior to FRS for predicting ACM (P, 0.05).
Risk categorization by machine learning
Based on TG-ROC analysis, the intermediate-risk range for the
LogitBoost model was a risk probability estimate of between 3.8
and 14%, corresponding to 90% sensitivity and specificity, respectively.
Low- and high-risk ranges were considered as either side of the inter-
mediate range. With this categorization, the number of patients as-
signed to low-, intermediate-, and high-risk groups in the study
population by the LogitBoost model were: 3960 (39%), 4768 (48%),
and 1302 (13%), respectively. The corresponding observed 5-year
ACM event rates in these risk-groups were 1.8, 6.7, and 27%,
respectively.
Calibration of machine learning scores
The Brier score for the LogitBoost model predicting ACM was 0.08
indicating good calibration between LogitBoost scores (estimated
predicted risk) and observed 5-year risk. A calibration plot also
confirmed good agreement between LogitBoost scores and the
observed 5-year risk of ACM (Figure 4).
Discussion
In this study, we observed ML methods to be an effective method
for the prediction of 5-year ACM. The ML method performed su-
periorly to clinical and CCTA summary metrics alone. To our
knowledge, this is the first large-scale evaluation of ML for prognos-
tic risk assessment using CCTA data. The observed efficacy suggests
ML has an important clinical role in evaluating prognostic risk in
individual patients with suspected CAD.
The ability to correctly identify high-risk patients who may benefit
from intensified preventative measures is a major challenge in
Figure 3 Receiver-operating characteristic curves for predic-
tion of 5-year all-cause mortality. Machine learning using feature
selection and a LogitBoost model had a significantly higher
area-under-the-curve for all-cause mortality prediction than all
other scores (P, 0.001)†. Area-under-the-curves for segment
stenosis score and segment involvement score were greater
than Framingham risk score (P, 0.05)
‡
. FRS, Framingham risk
score; SSS, segment stenosis score; SIS, segment involvement
score; DI, modified Duke index.
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Table 1 Baseline patient characteristics
Characteristic Data (n 5 10 030)








Current smoker 2432 (24)
Family history 3936 (39)
Chest pain, n (%)
Non-cardiac 1615 (16)
Atypical angina 2967 (30)
Typical angina 1820 (18)
Dyspnoea on exertion, n (%) 3224 (32)
CAD, coronary artery disease.
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cardiovascular medicine.22,23 Although traditional risk factors for
CAD offer general guidance and are effective tools for population-
based comparisons, they are ineffective for individual risk assess-
ments.23,24 Even when combined into global summary scores for
easy usage, the use of clinical variables alone is associated with sub-
stantial over- or under-treatment, emphasizing the need for more
precise assessment through patient-specific imaging.10,23
Appreciating and integrating the myriad risk predictors in an indi-
vidual patient is a challenge for the clinician. To date, efforts to im-
prove risk-stratification by using CCTA have largely relied upon
luminal stenosis severity. The emphasis placed on this variable
over others is in alignment with prior studies using invasive coronary
angiography, but ignores an array of other variables important in the
CAD pathogenic process, including coronary calcium content, pla-
que composition, and plaque burden.2,25 As an increasing number of
CCTA variables along with all clinical variables affecting risk need to
be considered, the complexity of assessment increases, making it
more difficult for a clinician to draw an overall conclusion regarding
risk in an individual patient. Furthermore, the potential influence of
unexpected interactions between several weaker predictors in an
individual patient is often overlooked. In this study, we demonstrate
that ML is able to overcome these challenges, by providing deep
integration of the comprehensive CCTA and clinical data.
We performed risk assessment using state-of-the-art ML meth-
ods, a form of artificial intelligence that distinguishes itself from trad-
itional prognostic methods by making no priori assumptions about
causative factors. This characteristic allows for an agnostic explor-
ation of all available data for non-linear patterns that may predict
a particular individual’s risk, i.e. precision risk-stratification. This im-
portant concept represents a divergence from a ‘hypothesis-driven’
approach conventional in traditional prognostic risk assessments. As
observed in the present study, the lack of any required hypothesis
avoids overlooking important but unexpected predictor variables
or interactions, as well as enabling the recognition of clinically im-
portant risk among patients with several marginal risk factors (or
no risk factors at all). Further, by its nature, any given ML algorithm
requires only minimal input during its model-building phase and
none after that. This feature of ML methods is particularly
important, given the ease with which the machine can seamlessly in-
corporate new data to continually update and optimize its algo-
rithm—and thus continually improve its predictive performance
over time.5,26
In a prior study, our group employed a traditional logistic regres-
sion approach to predict 2-year ACM, also based on data from the
CONFIRM registry.2 The resulting model comprised three clinical
and CCTA variables, and exhibited an AUC of 0.68. In the current
study, which extends follow-up to 5 years, ML methods offered an
incremental gain in prognostic performance while handling over 60
variables and a vast number of variable–variable interactions in each
patient. The latter effectively individualizes risk assessment and
overcomes many of the limitations of a standard statistical approach.
The results of this study have considerable clinical import. Prior
large-scale studies have documented the inadequacies of current
limited-variable methods for prediction of disease prevalence, se-
verity, and prognosis; and highlight the need for more accurate
methods to perform these important clinical tasks.27 – 29 As ob-
served in other fields that require accurate prediction and decision-
making in the presence of large amounts of data, ML may offer an
improved alternative to current cardiovascular risk-stratification in
the individual patient. These improvements may be furthered by
the emergence of standard electronic health records and software
capable of automated atherosclerotic plaque characterization and
quantification—both of which may improve any given ML algorithm.
A limitation of the ML approach is that by using an increasing
number of variables and interactions to predict risk, it can subse-
quently be difficult to identify the specific therapeutic targets that
will reduce risk in that individual patient. However, the current
therapeutic approach to CAD is very similar across all risk groups,
and the benefit of an incremental improvement in risk-stratification
in this context, even if a specific causative risk factor or interaction
cannot be identified, is that it may allow physicians to move away
from this ‘one-size fits all’ approach with confidence—with the ad-
vantage of cost-savings and reduced adverse effects in those that
currently receive unnecessary treatments. Furthermore, in time
those patients in whom ML re-classifies risk different from tradition-
al approaches can be prospectively studied in greater depth to iden-
tify the causative factors and interactions—and this may finally
unlock new therapeutic targets.
Study limitations
In the current study, we have only been able to discuss the feasibility
and performance of ML, but not its prospective practical implemen-
tation. The ability of any ML approach to handle a large number of
variables is only advantageous if these variables are actually inputted
into the ML algorithm—and this can be a time-consuming process,
depending on the mode of data entry. However, we envisage ML
working in the background of standard electronic health records
or clinical reporting systems, gathering its variables automatically
without additional burden on the physician—allowing on-the-fly
risk score computation. This is the same principle already adopted
by many ML applications—for example, the personalized advertise-
ments that appear in real-time while web-browsing are all based on
the passive collection of variables and their seamless input into ML
algorithms. In this regard, the feature selection component is
particularly important to future practical implementation as it
Figure 4 Calibration plot for LogitBoost model. The calibration
plot shows the relationship between the observed and predicted
proportion of events, grouped by decile of risk. The LogitBoost
model showed good calibration with the observed 5-year risk of
all-cause mortality.
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minimizes the amount of data needed to be handled by such an
on-the-fly ML application without compromising on accuracy.
Although prospectively collected, the CONFIRM registry data
used to derive the LogitBoost model was nevertheless observation-
al, and the influence of selection bias cannot be discounted. Obser-
vational cohort studies, however, are the best suited to assess the
initial feasibility of ML algorithms, given the requirement to both de-
velop and validate their efficacy. Once validated, prospective rando-
mized controlled treatment trials based upon ML risk-stratification
can then be considered. Whether an objective ML approach with-
out prior hypothesis is more effective than subjective but flexible
human thinking is an issue that future prospective studies may ex-
plore. Future prospective studies may also allow comparison of
our ML approach integrating CCTA and clinical data, to the alterna-
tive strategy in this study population of clinical assessment with
stress-testing.
Although alternative, more cardiac-specific endpoints than ACM
may have been utilized, these data were not available for all centres
in the CONFIRM registry. For the current study which had the aim
of demonstrating feasibility of the ML approach, ACM was the most
definitive end-point, with the maximal amount of patients to facili-
tate the best trained and validated ML model.
Although we evaluated 69 distinct variables with ML, along with
variable–variable interactions, we did not consider the totality of
features that may offer improved risk prediction, as we were limited
to those collected for the CONFIRM registry. In particular, more
detailed clinical data such as duration, magnitude and control of
risk factors, as well more advanced plaque characterization with %
aggregate plaque volume, arterial remodelling, or Hounsfield-
unit-based plaque composition classification, may augment the cur-
rent ML model.
Another limitation is the use of FRS as the summary metric for
evaluation of clinical parameters as it was originally validated for
10-year outcomes in asymptomatic patients. However, this is a com-
monly adopted strategy given the absence of any more suitable clinical
risk score for symptomatic patients or shorter follow-up periods, and
moreover, it frames the accuracy of the ML-model in the context of a
widely used and understood clinical score.2–4 Finally, while numerous
ML methods exist, we evaluated the efficacy of only a single ensemble
method (LogitBoost). In particular, boosting is also available for Cox-
based models (CoxBoost) which leads to the possibility of
time-to-event prediction using such alternative analysis.30
Conclusions
In a large, prospective 5-year multinational study of patients with
suspected CAD, ML was an effective method for the prediction of
ACM, and performed superiorly to the use of clinical and CCTA
variables alone.
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